Stockscreener 앱 받기
69.54
2.22%
-1.58
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Kymera Therapeutics, Inc. (KYMR) up 28% in 3M, analysts see further upside - MSN
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings) - Benzinga
BTIG Reiterates Buy Rating for Kymera Therapeutics (KYMR) with $ - GuruFocus
Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside - Finviz
Muted and missing M&As: JPM deals absent in 2026 - BioWorld MedTech
BTIG Research Reaffirms Buy Rating for Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
Kymera Therapeutics prices $602M public offering at $86.00 a share - MSN
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Portfolio of Oral Immunology Programs - marketscreener.com
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - Investing News Network
Kymera Therapeutics Sets 2026 Clinical Strategy and Milestones - TipRanks
Kymera Therapeutics (KYMR): Investor Outlook On Biotech's 59.75% Upside Potential - DirectorsTalk Interviews
Kymera Therapeutics Outlines 2026 Milestones, Advances Clinical Trials for Immunology Candidates - Quiver Quantitative
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - GlobeNewswire Inc.
Understanding the Setup: (KYMR) and Scalable Risk - Stock Traders Daily
Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why - Yahoo Finance
This drugmaker's stock is soaring over 40% Monday - MSN
Will Kymera Therapeutics Inc. stock maintain growth storyFootwear buying guidance for outdoor walking and light jogging focuses on support for wide feet, making it recommended when comfort and support matter. - ulpravda.ru
Why Kymera Therapeutics Inc. stock could see breakout soonMarket Trend Summary & Technical Buy Zone Confirmations - Улправда
Why Kymera Therapeutics Inc. stock is trending among retail traders2025 Price Momentum & AI Powered Buy/Sell Recommendations - Улправда
Kymera Therapeutics (NASDAQ:KYMR) Nasdaq Composite ETF Protein Regulation - Kalkine Media
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Is Kymera Therapeutics (KYMR) Balancing Pipeline Ambition and Execution Risk After New KT-621 Milestone? - Yahoo Finance
Kymera Advances KT-621 Into Mid-Stage Asthma Trial, Setting Up a New Catalyst for KYMR Investors - TipRanks
Kymera jumps on early-stage data for eczema candidate KT-621 - MSN
Kymera Therapeutics, Inc. (KYMR) Stock Analysis: A Biotech Leader with a 59.70% Potential Upside - DirectorsTalk Interviews
Kymera Therapeutics (KYMR) Downgraded by Wolfe Research | KYMR S - GuruFocus
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 - Investing News Network
Kymera Therapeutics CEO to unveil 2026 milestones at JPMorgan event - Traders Union
Wolfe Research downgrades Kymera Therapeutics stock rating on lack of catalysts - Investing.com Canada
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - sharewise.com
Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next - TechStock²
Kymera Therapeutics (KYMR) stock drops 6.6% to start 2026 as insider sale filing stays in focus - ts2.tech
KYMR Stock Falls -14% With A 7-day Losing Spree On Significant Insider Selling - Trefis
Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next - ts2.tech
Kymera Therapeutics (NASDAQ:KYMR) Trading Down 4.3%What's Next? - MarketBeat
Kymera Therapeutics (KYMR) Sees 4% Drop in Stock Price - GuruFocus
Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks - MarketBeat
The Technical Signals Behind (KYMR) That Institutions Follow - Stock Traders Daily
Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares - MarketBeat
Kymera Therapeutics Insider Sold Shares Worth $2,341,939, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics (NASDAQ: KYMR) CEO reports option exercise and share sale - Stock Titan
Kymera Therapeutics Earnings Notes - Trefis
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching - ts2.tech
Kymera Therapeutics announces results from BroADen Phase 1b trial of KT-621 - MSN
Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating - MSN
Kymera draws upgrades after early-stage data for anti-inflammatory agent - MSN
B. Riley Securities Maintains Kymera Therapeutics (KYMR) Buy Recommendation - Nasdaq
Why Kymera Therapeutics Stock Is Sliding Despite Hype - TipRanks
KYMR: B. Riley Securities Raises Price Target for Kymera Therape - GuruFocus
B. Riley Raises Price Target on Kymera Therapeutics to $117 From $80, Keeps Buy Rating - marketscreener.com
Can Kymera Therapeutics Inc. stock hit analyst price targets2025 Valuation Update & Daily Growth Stock Tips - Улправда
Squarepoint Ops LLC Cuts Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
What momentum indicators show for Kymera Therapeutics Inc. stockDividend Hike & Low Risk Entry Point Guides - ulpravda.ru
4.73%
0.92%
자본화:
|
볼륨(24시간):